Qurient acquires U.S. approval of Phase II clinical trial for MDR TB therapy Telacebec

Published: 2018-07-18 16:26:00
Updated: 2018-07-19 15:42:54

Qurient(CEO Ki-Yeon Nam) announced a beginning of a Phase II clinical to globally develop a multi-drug resistant(MDR) tuberculosis(TB) therapy on the 17th of July.

Qurient said the company will start the Phase II clinical trial for its First-in-Class MDR TB therapy Telacebec based on the Phase I...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.